Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
Cohen D, Hondelink LM, Solleveld-Westerink N, Uljee SM, Ruano D, Cleton-Jansen AM, von der Thüsen JH, Ramai SRS, Postmus PE, Graadt van Roggen JF, Hoppe BPC, Clahsen PC, Maas KW, Ahsmann EJM, Ten Heuvel A, Smedts F, van Rossem RN, van Wezel T. Cohen D, et al. Among authors: clahsen pc. J Thorac Oncol. 2020 Jun;15(6):1000-1014. doi: 10.1016/j.jtho.2020.01.019. Epub 2020 Jan 31. J Thorac Oncol. 2020. PMID: 32014610 Free article.
Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice.
Steeghs EMP, Vink GR, Elferink MAG, Voorham QJM, Gelderblom H, Nagtegaal ID; PATH Consortium Members; Grünberg K, Ligtenberg MJL; PATH consortium members. Steeghs EMP, et al. J Clin Pathol. 2021 Oct 21;75(10):706-11. doi: 10.1136/jclinpath-2021-207865. Online ahead of print. J Clin Pathol. 2021. PMID: 34675090 Free PMC article.
Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ. van Slooten HJ, et al. Among authors: clahsen pc. Br J Cancer. 1996 Jul;74(1):78-85. doi: 10.1038/bjc.1996.319. Br J Cancer. 1996. PMID: 8679463 Free PMC article. Clinical Trial.
High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJ, van den Broek LC, van de Vijver MJ. Elkhuizen PH, et al. Among authors: clahsen pc. J Clin Oncol. 2000 Mar;18(5):1075-83. doi: 10.1200/JCO.2000.18.5.1075. J Clin Oncol. 2000. PMID: 10694560 Clinical Trial.
Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.
Mandard AM, Denoux Y, Herlin P, Duigou F, van De Vijver MJ, Clahsen PC, van Den Broek L, Sahmoud TM, Henry-Amar M, van De Velde CJ. Mandard AM, et al. Among authors: clahsen pc. Cancer. 2000 Oct 15;89(8):1748-57. doi: 10.1002/1097-0142(20001015)89:8<1748::aid-cncr15>3.0.co;2-e. Cancer. 2000. PMID: 11042570 Clinical Trial.
Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators.
Clahsen PC, van de Velde CJ, Welvaart K, van Driel OJ, Sylvester RJ. Clahsen PC, et al. J Clin Oncol. 1995 Jan;13(1):33-41. doi: 10.1200/JCO.1995.13.1.33. J Clin Oncol. 1995. PMID: 7799039 Clinical Trial.
20 results